



# **Electronic Publication of Patents Journal under The Patents (Amendments) Act, 2016**

Weekending:- 10-11-2017

Legal Publication Date:- 22-11-2017

Journal Code (1711222)

**NEW APPLICATIONS FOR THE PATENTS**

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

<b>06-11-2017</b>		
572/2017	<b>SANOFI</b> France (Priority 07-11-2016 EP)	“SUBSTITUTED PYRIDO[3,4-B]INDOLES AND THEIR USE AS PHARMACEUTICALS”
573/2017	<b>ELI LILLY AND COMPANY</b> USA <b>AUDION THERAPEUTICS</b> Netherlands (Priority 07-07-2015 US) <b>Divisional</b>	“Pharmaceutically acceptable salt of N-(2S)-1-(8,8-dimethyl-6-oxo-6,8,9,10-tetrahydro-5H-pyrido[3,2-f]pyrrolo[1,2-a]azepin-5-yl)amino)-1-oxopropan-2-yl)-4,4,4-trifluorobutanamide compound and pharmaceutical composition thereof”
<b>08-11-2017</b>		
574/2017	UPL LTD, India (Priority 09-11-2016 IN)	“TERNARY HERBICIDAL COMBINATION”
575/2017	APEX GLORY HOLDING LTD. Island (Priority 10-11-2016 TAIWAN)	“OPERATING STRUCTURE OF SURGICAL CLIP APPLIER”
576/2017	Novartis AG Switzerland (Priority 10-11-2016 US)	“BMP POTENTIATORS”
<b>09-11-2017</b>		
577/2017	Meiji Co Ltd Japan (Priority 10-11-2016 JP)	“THERMAL PROCESSING METHOD OF MICROORGANISM”

578/2017	KANG HO LIM USA	"Steel NiTi Flexible material"
<b>10-11/2017</b>		
579/2017	CELL THERAPY AND TECHNOLOGY, S.A. DE C.V. Mexico (Priority 11-11-2016 MX)	"Pharmaceutical use of a composition containing pirfenidone of extended-release for treatment and reversal of human steatohepatitis (Nafld/Nash)"


**APPLICATION ACCEPTED**


Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Patents' journal may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.


109/2006	Syngenta Participations AG Switzerland Syngenta Limited United Kingdom.	<p>"A process for the preparation of substituted benzene for use in the production of 3-hydroxy-4-aryl-5-oxopyrazoline compound"</p> <p>C07C17/093 &amp; C07C25/02.</p> <p style="text-align: right;"><b>142628</b></p> <p>The present invention provides a process for the production of intermediate compounds of formula I</p> <div style="text-align: center;">  </div>
----------	--	---

		<p>wherein the substituents are as defined herein.</p> <p>The process comprises reacting a substituted aniline with aqueous HX, followed by removal of water by azeotropic distillation and diazotization and pyrolysis with an organic nitrite at elevated temperatures in the absence of a copper catalyst. Alternatively, gaseous HX can be used to substitute aqueous HX in the process. Consequently, a step of water removal by azeotropic distillation can be eliminated. The intermediate compounds of formula I are suitable as intermediates in the preparation of herbicidally active 3-hydroxy-4-aryl-5-oxopyrazoline derivatives.</p>
<p>190/2009</p>	<p>1) IRM LLC. Bermuda. 2) NOVARTIS AG Switzerland.</p>	<p>"SUBSTITUTED BENZO[f][1,7]NAPHTHYRIDINE COMPOUND"</p> <p>A61K31/4375 &amp; A61P37/04.</p> <p style="text-align: right;"><b>142629</b></p> <p>The invention provides a novel class of compound of formula I</p> <div style="text-align: center;">  </div> <p>pharmaceutical composition comprising such compound to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In</p>

		<p>one aspect, the compound is useful as adjuvants for enhancing the effectiveness of a vaccine.</p>
<p>758/2010</p>	<p>RENSELAER POLYTECHNIC INSTITUTE U.S.A.</p>	<p>"K5 heparosan fermentation and purification" C12P19/04, C12N1/20 &amp; C08B37/10. <b>142630</b></p> <p>A method for the production of heparosan from fermentation culture of E. coli K5 suitable for industrial production, exhibiting superior yield and purity, smaller culture volumes, faster growth, and lower costs.</p>

<p>122/ 2014</p>	<p>Eisai R&amp;D Management Co., Ltd. Japan.</p>	<p>" TETRAHYDROIMIDAZO[1,5-d] [1,4]OXAZEPINE DERIVATIVE"  C07D498/04, A61K31/553 &amp; A61P25/28.</p> <p style="text-align: right;"><b>142631</b></p> <p>A compound represented by the following formula (I) works as an mGluR2 antagonist, and is applicable as a therapeutic agent for neurological disorders related to glutamate dysfunction and diseases involving the mGluR2, such as Alzheimer's disease:</p> <div style="text-align: center;"> </div> <p>wherein R is a hydrogen atom, a C<sub>1-6</sub> alkyl group or the like, R<sub>1</sub> is a C<sub>1-6</sub> alkyl group, a C<sub>1-6</sub> alkoxy group or the like, R<sub>2</sub> is a halogen atom, a C<sub>1-6</sub> alkyl group, a C<sub>1-6</sub> alkoxy group or the like, R<sub>3</sub> is a hydrogen atom, a C<sub>1-6</sub> alkyl group or the like, and R<sub>4</sub> is a C<sub>1-6</sub> alkyl group or the like.</p>
<p>251/ 2016</p>	<p>Eisai R&amp;D Management Co., Ltd. Japan.</p>	<p>" PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT OF TETRAHYDROIMIDAZO[1,5-d][1,4]OXAZEPINE DERIVATIVE"</p> <p style="text-align: right;"><b>142632</b></p>

A pharmaceutically acceptable salt of a compound represented by the following formula (I) works as an mGluR2 antagonist, and is applicable as a therapeutic agent for neurological disorders related to glutamate dysfunction and diseases involving the mGluR2, such as Alzheimer's disease:



wherein R is a hydrogen atom, a C<sub>1-6</sub> alkyl group or the like, R<sub>1</sub> is a C<sub>1-6</sub> alkyl group, a C<sub>1-6</sub> alkoxy group or the like, R<sub>2</sub> is a halogen atom, a C<sub>1-6</sub> alkyl group, a C<sub>1-6</sub> alkoxy group or the like, R<sub>3</sub> is a hydrogen atom, a C<sub>1-6</sub> alkyl group or the like, and R<sub>4</sub> is a C<sub>1-6</sub> alkyl group or the like.



**NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS**

<b>S. No.</b>	<b>Design No.</b>	<b>Title &amp; Class</b>	<b>Applicant</b>
<b><u>07/11/2017</u></b>			
1.	18978	Ink Drop Bottle (Class-3)	Sayyed Engineers Limited
2.	18979	Packing Carton (Class-5)	Hefei Yili Dairy Co.,Ltd.,
3.	18980	Sharpner (Class-3)	Sayyed Engineers Limited
<b><u>09/11/2017</u></b>			
4.	18981	Ballpoint Pen (Class-03)	Sayyed Engineers Limited
5.	18982	Ballpoint Pen (Class-03)	Sayyed Engineers Limited
6.	18983	Front Grille For Automobile (Class-03)	HONDA MOTOR CO., LTD.
7.	18984	Front Combination Lamp For Automobile (Class-03)	HONDA MOTOR CO., LTD.
8.	18985	Front Bumper For Automobile (Class-03)	HONDA MOTOR CO., LTD.
<b><u>10/11/2017</u></b>			
9.	18986	Dry Fruit/Cake Rack (Class-03)	EMSA PLASTIC INDUSTRIES
10.	18987	Cement Bag (Class-05)	M/s Fauji Cement Company Limited

**REGISTRATION OF DESIGNS**

The following designs have been registered.

S. No.	Design No.	Title & Class	Applicant
<b><u>10/11/2017</u></b>			
1.	17970	Serving Dish with Lid (Class-03)	DOVE MELAMINE WARE
2.	17971	Plate (Class-03)	DOVE MELAMINE WARE
3.	18058	Tablet Dispenser (Class-03)	MARRIANA International
4.	18170	Geometry Box (Class-12)	Sayyed Engineers Limited



(Dr. Muhammad Fayyaz Ahmad)  
 Controller of Patents  
 & Registrar of Designs  
 Ph: 99230591